1xbet 카지노 Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) is pleased to announce that Otsuka Novel Products GmbH, a Germany based subsidiary 1xbet 카지노 Otsuka Pharmaceutical, has obtained regulatory approval from the European Commission for the Deltyba™ (delamanid) 25-mg dispersible tablet formulation. This formulation 1xbet 카지노 Deltyba is for use as part 1xbet 카지노 a drug treatment regimen, when an effective treatment regimen cannot otherwise be composed, for children weighing at least 10 kg who have pulmonary multidrug-resistant tuberculosis (MDR-TB).

The Global Tuberculosis Report 2020 produced by the World Health Organization notes that 1.2 million children (ages 0 to14) suffered from tuberculosis (TB) 1xbet 카지노 2019.^*1Also, according to a paper published in The International Journal 1xbet 카지노 Tuberculosis and Lung Disease, between 25,000 and 32,000 children worldwide develop MDR-TB each year, and it is likely that around 22 percent 1xbet 카지노 children developing MDR-TB will die.^*2One 1xbet 카지노 the new global goals that was set at the United Nations General Assembly High-Level Meeting on TB in 2018 was to treat 115,000 children with drug-resistant TB over a five-year period.^*3

Masanori Kawasaki, Global TB Project leader at Otsuka Pharmaceutical, said, "Otsuka Pharmaceutical has been conducting TB research and development for many years with the aims to deliver therapeutic drugs to as many patients as possible and ultimately eradicate TB around the world. We hope that the newly approved dosage form 1xbet 카지노 Deltyba will contribute to the treatment 1xbet 카지노 MDR-TB in children. We will continue to pursue the SDG goals, especially Good Health and Well-Being (goal #3), through the development 1xbet 카지노 anti-TB drugs."

About delamanid

Delamanid (brand name is Deltyba) is a compound created by Otsuka Pharmaceutical with a new mechanism 1xbet 카지노 action with anti-TB activity that occurs through inhibition 1xbet 카지노 the synthesis 1xbet 카지노 mycolic acid, an essential component 1xbet 카지노 mycobacterial cell wall.
Currently, delamanid is approved in Europe, Japan, South Korea, China, India, South Africa, Russia and other countries. It was added to the WHO Model List 1xbet 카지노 Essential Medicines in 2015 and to date has been used to treat patients with MDR-TB in more than 110 countries. Last year in Europe, approval was granted for Deltyba 50 mg film-coated tablets to be used in children and adolescents weighing at least 30 kg.

1. 1World Health Organisation. Global Tuberculosis Report 2020. Available at:https://www.who.1xbet 카지노t/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020(Last accessed Sept. 2021)
2. 2Jenkins H, et al. The burden 1xbet 카지노 multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018; 22: 3-6.
3. 3UN High Level Meet1xbet 카지노g on TB 2018 - Key Targets and Commitments. Available at:
   http://www.stoptb.org/assets/documents/global/advocacy/unhlm/UNHLM_Targets&Commitments.pdf(Last accessed Sept. 2021)